The kidney cancer drugs market is anticipated to grow at a considerable 7.1% CAGR during the forecast year. The major factor that drives the global kidney cancer drug market during the forecast period is the increasing number of people suffering from kidney cancer. As per the American Cancer Society’s recent estimates, in 2019, there were about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women). Kidney and renal pelvis cancer represent 4.2% of all new cancer cases in the United States. It was estimated that there were around 14,770 deaths in 2019, owing to Kidney and renal pelvis cancer. Furthermore, the increasing utilization of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective.
Moreover, the market is also growing due to the new product launches. For instance, in September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib. The drug is available in 20mg/40mg/60mg strengths for the treatment of renal cell carcinoma. Furthermore, in February 2021, Glenmark Pharma launched a generic of ‘Sunitinib oral capsules’ for the treatment of kidney cancer in India. The drug was priced 96% lower compared to the innovator brand.
Some major players in the market include Novartis International AG, Bristol-Myers Squibb Co., and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, BDR Pharma launched a generic version of Pazopanib in the Indian market. The drug is used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma.
To Request a Sample of our Report on Kidney Cancer Drugs Market: https://www.omrglobal.com/request-sample/kidney-cancer-drugs-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Cancer Type
- By End-User
Regions Covered–
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Novartis International AG, Bristol-Myers Squibb Co., and Merck & Co., Inc., among others.
Kidney Cancer Drugs Market Report by Segment
By Cancer Type
- Clear cell RCC
- Papillary RCC
- Chromophobe RCC
- Urothelial carcinoma/Transitional cell carcinoma
- Others
By End-User
- Hospitals
- Clinics
- Others
A full Report of Kidney Cancer Drugs Market is Available @ https://www.omrglobal.com/industry-reports/kidney-cancer-drugs-market
Kidney Cancer Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
